Lymphoma

San Diego, CA—Obinutuzumab (Gazyva)-based induction and maintenance chemotherapy extended progression-free survival (PFS) compared with standard-of-care rituximab (Ritux­an)-based chemotherapy in patients with untreated follicular lymphoma, said Robert E. Marcus, MBBS, FRCP, FRCPath, King’s College Hospital, London, who presented the results from the phase 3 GALLIUM clinical trial at the 2016 American Society of Hematology meeting.
San Diego, CA—The CALGB/Alliance 50303 clinical trial failed to show that dose-adjusted treatment with the EPOCH-R (etoposide, phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride, and rituximab) regimen was superior to standard therapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone) in patients with diffuse large B-cell lymphoma (DLBCL). Both treatment regimens were equally effective for event-free survival (EFS) and overall survival (OS), but dose-adjusted EPOCH-R was associated with a higher incidence of adverse events than R-CHOP, said lead investigator Nancy L. Bartlett, MD, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, at the 2016 American Society of Hematology meeting.
San Diego, CA—The PD-1 inhibitor pembrolizumab (Keytruda) has good activity in patients with relapsed or refractory mycosis fungoides or Sézary syndrome, and the responses it produces are deep and durable, according to study results reported by Michael Khodadoust, MD, PhD, Medicine-Oncology, Division of Oncology, Stanford University School of Medicine, CA, at the 2016 American Society of Hematology meeting.
San Diego, CA—Brentuximab vedotin (Adcetris) monotherapy significantly improved the objective response rate (ORR) lasting ≥4 months compared with the investigator’s choice of standard therapy in patients with cutaneous T-cell lymphoma (CTCL), reported Youn H. Kim, MD, Director, Multidisciplinary Cutaneous Lymphoma Clinic, Stanford University School of Medicine, CA, at the 2016 American Society of Hematology meeting.
Two programmed-cell death receptor-1 (PD-1) inhibitors—the investigational drug nivolumab and the recently approved pembrolizumab (Keytruda)—produced dramatic responses in patients with Hodgkin lymphoma in phase 1 clinical trials.
Early posttransplant consolidation with brentuximab vedotin (Adcetris) significantly improved progression-free survival (PFS) compared with placebo in patients with Hodgkin lymphoma who are at risk for disease progression in the placebo-controlled phase 3 AETHERA trial.
Patients with HIV-­related lymphoma should not be excluded from clinical trials of autol­ogous hematopoietic-cell transplant (AHCT). Moreover, they should be offered AHCT as a standard treatment option, according to the results of a phase 2 trial reported at the 2014 American Society of Hematology meeting.
New Orleans, LA—Treatments for non-Hodgkin lymphoma (NHL) may take a new turn with several inhibitors of the PI3 kinase (PI3K) nearing approval. PI3K-delta signaling is critical for B-cell activation, proliferation, and survival, and it is hyperactive in many B-cell malignancies.
New Orleans, LA—In patients with transformed indolent lymphoma (TrIL) who achieve a complete metabolic remission, surveillance scanning with positron emission tomography–computed tomography (PET-CT) is of limited clinical benefit, based on results of a retrospective analysis presented at ASH 2013.
New Orleans, LA—Findings from 2 major studies presented at ASH 2013 indicate that the longer the maintenance period, the greater the duration of progression-free survival (PFS) in follicular lymphoma (FL); however, overall survival (OS) was still not improved, even at 6 years of follow-up.
Page 1 of 2
Results 1 - 10 of 15
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME